At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 20 target
Drug / intervention
CC-EIEsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Innovative Treatment of Cervical Cancer Using Engineered Antigen-specific Immune Effectors (EIEs)
In Brief
A Phase 1 clinical trial evaluating CC-EIEs for Cervical Cancer. Currently recruiting, targeting 20 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
The primary objective of this study is to evaluate the safety of cervical cancer specific engineered immune effectors (CC-EIEs). The secondary objectives are to evaluate the rate of successful CC-EIE generation in vitro and determine the anti-CC efficacy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
20182019202020212022202320242025202620272028202920302031
First PostedDec 2017
Enrollment StartJun 2026
TodayJul 2026
Primary CompletionDec 2029
Study CompletionDec 2030
First PostedDec 5, 2017
Enrollment StartJun 1, 2026
Primary CompletionDec 31, 2029
Study CompletionDec 31, 2030
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 8.6 years agoPrimary completion in 3.5 years
Arms & Interventions
CC-EIEsexperimental
Autologous cervical cancer specific engineered immune effectors (EIEs)
Biological: CC-EIEs
Interventions
CC-EIEsbiological
2 to 4 infusions, once a week, for 1x10\^5\~1x10\^7 CTLs/kg via IV, abdominal cavity or intratumoral injection each time